Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes

DOI PDF 被引用文献5件 参考文献37件
  • Yachiyo Kuwatsuka
    Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya;
  • Koichi Miyamura
    Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya;
  • Ritsuro Suzuki
    Department of HSCT Data Management, Nagoya University School of Medicine, Nagoya;
  • Masaharu Kasai
    Department of Hematology, Sapporo Hokuyu Hospital, Sapporo;
  • Atsuo Maruta
    Department of Hematology, Kanagawa Cancer Center, Yokohama;
  • Hiroyasu Ogawa
    Department of Molecular Medicine, Osaka University Graduate School of Medicine, Osaka;
  • Ryuji Tanosaki
    Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo;
  • Satoshi Takahashi
    Department of Hematology, Institute of Medical Science, The University of Tokyo, Tokyo;
  • Kyuhei Koda
    Department of Hematology, Asahikawa Red Cross Hospital, Asahikawa;
  • Kazuhiro Yago
    Department of Hematology, Shizuoka General Hospital, Shizuoka;
  • Yoshiko Atsuta
    Department of HSCT Data Management, Nagoya University School of Medicine, Nagoya;
  • Takashi Yoshida
    Hematology Department, Toyama Prefectural Hospital, Toyama; and
  • Hisashi Sakamaki
    Department of Hematology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
  • Yoshihisa Kodera
    Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya;

説明

<jats:p>We analyzed 338 adult patients with acute myeloid leukemia (AML) with t(8;21) and inv(16) undergoing stem cell transplantation (SCT) who were registered in the Japan Society for Hematopoietic Cell Transplantation database. At 3 years, overall survival (OS) of patients with t(8;21) and inv(16) was 50% and 72%, respectively (P = .002). Although no difference was observed when restricted to allogeneic SCT in first complete remission (CR; 84% and 74%), OS of patients with t(8;21) and inv(16) undergoing allogeneic SCT in second or third CR (45% and 86% at 3 years; P = .008) was different. OS was not different between patients in first CR who received allogeneic SCT and those who received autologous SCT for both t(8;21) AML (84% vs 77%; P = .49) and inv(16) AML (74% vs 59%; P = .86). Patients with inv(16) not in CR did better after allogeneic SCT than those with t(8;21) (70% and 18%; P = .03). Patients with t(8;21) and inv(16) should be managed differently as to the application of SCT. SCT in first CR is not necessarily recommended for inv(16). For t(8;21) patients in first CR, a prospective trial is needed to clarify the significance of autologous SCT and allogeneic SCT over chemotherapy.</jats:p>

収録刊行物

  • Blood

    Blood 113 (9), 2096-2103, 2009-02-26

    American Society of Hematology

被引用文献 (5)*注記

もっと見る

参考文献 (37)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ